Peyton Greenside, Ph.D., is the co-founder and CEO of BigHat Biosciences, a biotechnology company pioneering the integration of machine learning and synthetic biology to accelerate the design of next-generation antibody therapeutics. She brings a deep background at the intersection of computational biology, machine learning and biology, with prior experience as an inaugural Schmidt Science Fellow and as a computational biologist at the Broad Institute. Greenside has a doctorate in biomedical informatics from Stanford University, a Master of Philosophy from the University of Cambridge as a Herchel Smith scholar and a Bachelor of Arts from Harvard University.
Earlier this year, Greenside transitioned from chief scientific officer to CEO, where she now drives BigHat’s overall vision, strategy and growth. She oversees research and development, business development, operations and culture, ensuring alignment across a fast-growing, interdisciplinary team. Her leadership has been central to raising more than $140 million in venture funding and establishing strategic partnerships with leading pharmaceutical companies, including Amgen, Merck, AbbVie, Johnson & Johnson and Eli Lilly.
Greenside has been a trailblazer in applying artificial intelligence/machine learning to biologics, advancing BigHat’s proprietary Milliner platform to deliver higher-quality therapeutics faster and more efficiently. Under her stewardship, BigHat is expanding its internal therapeutic pipeline and broadening its impact through industry collaborations. Recognized as both a scientist and a leader, Greenside continues to shape the future of drug discovery by combining scientific rigor with strategic execution and a mission-driven approach to improving patient outcomes.